Firefly Neuroscience Closes on Financing of up to $12.4 Million
TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence...
Brain
AI Wellness Launches Groundbreaking 2025 Initiatives to Celebrate Visionaries, Innovators, and Clinics
LAS VEGAS, Dec. 30, 2024 /PRNewswire/ -- Assisted Intelligence Wellness Inc. (AI Wellness), a global leader in integrating AI with personalized...
Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®
Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025BRAINTREE, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Microbot...
Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia
RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1...
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.
Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company’s pipelinePALO ALTO, Calif., Dec....
NAVIGANTIS VASCO™ Robotic Platform Used with First Patients Enrolled in Neurovascular Study
MIAMI, Dec. 27, 2024 /PRNewswire/ -- Navigantis Inc. announced today the first successful neurovascular clinical cases performed with its VASCO interventional...
Honeycomb Clinic Positions for Public Offering
Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024 / Honeycomb Clinic, the innovative...
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company", an emerging leader in...
Mentavi Health Offers Tips and Tools to Help Manage Stress During the Holiday Season
Nearly half of all Americans feel more pressure from time commitments, stretched finances, gift-giving, and family gatherings. Mentavi, a leader...
RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in Breast and Gastric...
Darmiyan Enters Medicare GUIDE Program Through Partnership with Five Star Home Health Care, CareBrains, and Brain Watch Coalition
SAN FRANCISCO, Dec. 19, 2024 /PRNewswire/ -- Darmiyan, Inc., a leader in brain health technology, proudly announces its participation in...
Lexaria’s Registered GLP-1 Study #4 Begins Dosing
Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss KELOWNA, BC / ACCESSWIRE / December 19, 2024...
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications
Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indicationsThe import was conducted...
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company’s Pipeline Development
MIAMI, FL / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing...
ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21
FREMONT, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative...
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
– A-005 was well tolerated and demonstrated ability to cross blood-brain barrier – – Maximal TYK2 inhibition achieved with favorable...
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
If approved, UX111 would be the first approved therapy in the U.S. for Sanfilippo Syndrome Type ANOVATO, Calif., Dec. 19,...
Rakovina Therapeutics: Reflecting on 2024 Success and Building Momentum for a Transformative 2025
VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) a biopharmaceutical...
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom’s MacroglobulinemiaSAN FRANCISCO, Dec. 19,...
Best Mounjaro Alternative Over the Counter: Cheaper, Safer Alternatives to Tirzepatide OTC
If you are considering a natural over the counter Mounjaro alternative for 2025 - we have the top 3 options...